Montelukast Heumann

Montelukast, the active ingredient in Montelukast Heumann, is a leukotriene receptor antagonist presented as an oral tablet for systemic use. It is employed to manage chronic asthma, allergic rhinitis, and exercise‑induced bronchoconstriction in adult and pediatric patients as directed by a healthcare professional.

GNH USA supplies Montelukast Heumann as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product meets EU quality standards and is manufactured under strict GMP conditions.

Montelukast acts on the leukotriene pathway to control inflammation and bronchoconstriction in several allergic respiratory conditions.

- Asthma: reduces frequency of symptoms and improves lung function in persistent asthma. - Allergic rhinitis: alleviates nasal congestion, sneezing and itching caused by seasonal or perennial allergens. - Exercise‑induced bronchoconstriction: prevents airway narrowing triggered by physical activity.

Montelukast may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate pain often occurring early in therapy. - Abdominal pain: discomfort or cramps in the stomach region. - Cough: transient dry cough. - Diarrhea: loose stools. - Nasopharyngitis: common cold‑like symptoms. - Fatigue: feeling of tiredness.

Serious or Rare Side Effects: - Neuropsychiatric events: agitation, depression, suicidal thoughts. - Allergic reactions: rash, urticaria, angioedema. - Hepatotoxicity: elevated liver enzymes or hepatitis. - Stevens‑Johnson syndrome: severe skin blistering. - Anaphylaxis: rapid onset of systemic allergic response.

When prescribing Montelukast, clinicians should consider several safety and monitoring points.

- Monitor liver function: assess transaminases in patients with hepatic disease. - Use caution in psychiatric history: observe for mood changes or suicidal ideation. - Avoid in known hypersensitivity: discontinue if rash or angioedema occurs. - Not for acute asthma attacks: provide rescue bronchodilator instead. - Adjust in renal impairment: consider dose reduction in severe renal failure. - Store at room temperature: keep in original container, protect from moisture and light.

Montelukast has documented interactions that may alter its effectiveness or increase risk of adverse effects.

Major Interactions (Avoid): - Phenobarbital: enzyme induction reduces montelukast plasma levels. - Rifampin: strong CYP inducer decreases therapeutic exposure. - Carbamazepine: induces metabolism leading to loss of efficacy.

Moderate Interactions (Monitor Closely): - Ketoconazole: CYP3A4 inhibition may increase montelukast concentration. - Erythromycin: moderate increase in drug levels. - Fluconazole: may raise plasma concentrations modestly. - Warfarin: potential alteration of anticoagulant effect; monitor INR.